Long-term Outcomes Following Multimodal Therapy in Patients with Metastatic Uveal Melanoma: A Case Study - Scorecard - MDSpire

Long-term Outcomes Following Multimodal Therapy in Patients with Metastatic Uveal Melanoma: A Case Study

  • By

  • Francesca Rifaldi

  • Martina Angi

  • Giuseppe Leone

  • Marta De Ponti

  • Marta Vaiani

  • Andrea Spagnoletti

  • Alice Indini

  • Michele Del Vecchio

  • Lorenza Alessia Di Guardo

  • April 24, 2026

  • 0 min

Share

Clinical Scorecard: Long-term Outcomes Following Multimodal Therapy in Patients with Metastatic Uveal Melanoma: A Case Study

At a Glance

CategoryDetail
Condition
Key MechanismsTebentafusp's synergy with radiotherapy for enhanced immunogenic modulation.
Target Population
Care Setting

Key Highlights

  • Highlight the necessity of HLA-A*02:01 testing for patient selection.

Guideline-Based Recommendations

Diagnosis

  • Confirm metastatic uveal melanoma through imaging (CT/MRI) and HLA-A*02:01 testing.

Management

    Monitoring & Follow-up

    • Regular imaging (CT/MRI) to assess treatment response and disease progression.

    Risks

      Patient & Prescribing Data

      Tebentafusp combined with SBRT may enhance treatment efficacy and patient quality of life, particularly in liver metastases.

      Clinical Best Practices

      • Integrate multimodal therapies, including specific examples like tebentafusp and SBRT.

      References

      Original Source(s)

      Long-term Outcomes Following Multimodal Therapy in Patients with Metastatic Uveal Melanoma: A Case Study

      • by Francesca Rifaldi, Martina Angi, Giuseppe Leone, Marta De Ponti, Marta Vaiani, Andrea Spagnoletti, Alice Indini, Michele Del Vecchio, Lorenza Alessia Di Guardo

      • April 24, 2026

      Related Content

      Case Report: Synovial sarcoma with diffuse myxoid stroma and complete absence of epithelial differentiation in the extremity

      Treatment evolution and survival impact of consolidation therapies in mantle cell lymphoma: insights from an Asia-Pacific real-world registry

      Stimuli-responsive nanoplatforms for sonodynamic immunotherapy: opportunities and challenges in cancer treatment